BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 11, 2018

Primary Completion Date

December 15, 2023

Study Completion Date

December 15, 2028

Conditions
LymphomaAdult T-Cell Leukemia/LymphomaLymphatic Diseases
Interventions
DRUG

Brentuximab Vedotin

Brentuximab Vedotin will be given at 1.8 mg/kg IV over approximately 30 minutes on D1 every 21 days for 2-6 cycles. Responders (CR, PR or SD) who are not eligible for bone marrow transplant (BMT) and have CD30-positive ATLL will continue maintenance therapy with BV alone (1.8 mg/kg IV for approximately 30 minutes, every 21 days).

DRUG

CHEP

"Cyclophosphamide- 750 mg/m\^2 IV over approximately 1 hour on D1 every 21 days for 2-6 cycles~Doxorubicin- 50 mg/m\^2 IV over approximately 3-5 minutes on D1 every 21 days for 2-6 cycles.~Etoposide - 100 mg/m\^2 IV over approximately 1 hour each day for 3 days every 21 days for 2-6 cycles.~Prednisone - 100 mg, orally once daily for 5 days every 21 days for 2-6 cycles."

Trial Locations (4)

27599

Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill, Chapel Hill

33021

South Broward/Memorial Healthcare System, Hollywood

02118

Boston Medical Center, Boston

02215

Beth Israel Deaconess Medical Center (BIDMC), Boston

All Listed Sponsors
collaborator

Seagen Inc.

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT03264131 - BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma | Biotech Hunter | Biotech Hunter